Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OsteoporeASX:OSX +12.50% 3-Year EPS without NRI Growth Rate is 39.40% as of Dec. 2025, which is 73% above its 10-year median of 22.75. The stock has 7 warning signs investors should review. Among 658 Medical Devices & Instruments companies, Osteopore ranks better than 84.35% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 39.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 16.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Osteopore was 39.40% per year. The lowest was -20.50% per year. And the median was 22.75% per year.
Osteopore (ASX:OSX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Osteopore 3-Year EPS without NRI Growth Rate Related Terms
ASX:OSX vs ISRG, BDX, MDLN: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Osteopore's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Osteopore 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Osteopore's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Osteopore's 3-Year EPS without NRI Growth Rate falls into.
Osteopore 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 39.40% mean?
Osteopore (ASX:OSX) has a 3-Year EPS without NRI Growth Rate of 39.40% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Osteopore and its competitors. This is 73% above median its historical median of 22.75. According to the industry distribution chart, Osteopore ranks #103 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 15.7%.
Is Osteopore's 3-Year EPS without NRI Growth Rate too high?
Osteopore's current 3-Year EPS without NRI Growth Rate of 39.40% is 73% above median its 10-year median of 22.75. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. Osteopore's value of 39.40% is 389.4% above this industry median. Based on the distribution chart, Osteopore ranks #103 out of 658 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Osteopore's 3-Year EPS without NRI Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Osteopore ranks #103 out of 658 companies for 3-Year EPS without NRI Growth Rate. This places Osteopore in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 8.05. Osteopore's value of 39.40% is 389.4% above this benchmark. While the company's 10-year median is 22.75 vs. the industry median of 8.05, Osteopore has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Osteopore's current 3-Year EPS without NRI Growth Rate of 39.40% is 389.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Osteopore and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Osteopore's current 3-Year EPS without NRI Growth Rate is 39.40%, which is 73% above median its own 10-year median of 22.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 77.5% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 39.40%, which is 73% above median its 10-year median of 22.75 and 389.4% above the Medical Devices & Instruments industry median of 8.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current 3-Year EPS without NRI Growth Rate is 39.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSX has been successfully added to your 
